Palatability of angiotensin II antagonists among nephropathic children

被引:21
作者
Meier, Chiara M.
Simonetti, Giacomo D.
Ghiglia, Silvia
Fossali, Emilio
Salice, Patrizia
Limoni, Costanzo
Bianchetti, Mario G. [1 ]
机构
[1] San Giovanni Hosp, Dept Pediat, CH-6500 Bellinzona, Switzerland
[2] Univ Bern, Inselspital, Dept Pediat, CH-3010 Bern, Switzerland
[3] IRCCS, Fdn Osped Maggiore Policlin Mangiagalli & Regina, Milan, Italy
[4] Univ Appl Sci So Switzerland, Dept Econ & Social Sci, Manno, Switzerland
关键词
candesartan cilexetil; hypertension; irbesartan; losartan; palatability; telmisartan; valsartan;
D O I
10.1111/j.1365-2125.2006.02814.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aims Angiotensin II receptor blockers are widely prescribed in kidney disease. Among children, medication palatability is crucial for adherence. Methods Taste and smell acceptability of five angiotensin II receptor blockers were compared among 21 nephropathic children using a visual analogue scale palatability score. Results The score assigned to pulverized tablets of candesartan cilexetil was significantly higher than that assigned to pulverized tablets of irbesartan, losartan, telmisartan and valsartan. Conclusions the perspective of the nephropathic child, the taste of pulverized candesartan cilexetil is superior to that of irbesartan, losartan, telmisartan or valsartan.
引用
收藏
页码:628 / 631
页数:4
相关论文
共 12 条
[1]  
Conlin Paul R., 2000, J Clin Hypertens (Greenwich), V2, P253
[2]   Antihypertensive and renoprotective efficacy and safety of losartan - A long-term study in children with renal disorders [J].
Ellis, D ;
Moritz, ML ;
Vats, A ;
Janosky, JE .
AMERICAN JOURNAL OF HYPERTENSION, 2004, 17 (10) :928-935
[3]   Long-term antiproteinuric and renoprotective efficacy and safety of losartan in children with proteinuria [J].
Ellis, D ;
Vats, A ;
Moritz, ML ;
Reitz, S ;
Grosso, MJ ;
Janosky, JE .
JOURNAL OF PEDIATRICS, 2003, 143 (01) :89-97
[4]   Effectiveness and safety of the angiotensin II antagonist irbesartan in children with chronic kidney diseases [J].
Franscini, LMD ;
Von Vigier, RO ;
Pfister, R ;
Casaulta-Aebischer, C ;
Fossali, E ;
Bianchetti, MG .
AMERICAN JOURNAL OF HYPERTENSION, 2002, 15 (12) :1057-1063
[5]   Better renoprotective effect of angiotensin II antagonist compared to dihydropyridine calcium channel blocker in childhood [J].
Gartenmann, AC ;
Fossali, E ;
von Vigier, RO ;
Simonetti, GD ;
Schmidtko, J ;
Edefonti, A ;
Bianchetti, MG .
KIDNEY INTERNATIONAL, 2003, 64 (04) :1450-1454
[6]   Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension [J].
Israili, ZH .
JOURNAL OF HUMAN HYPERTENSION, 2000, 14 (Suppl 1) :S73-S86
[7]   Why do they do that? - The compliance conundrum [J].
Nevins, TE .
PEDIATRIC NEPHROLOGY, 2005, 20 (07) :845-848
[8]   Formulation of medicines for children [J].
Nunn, T ;
Williams, J .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 59 (06) :674-676
[9]   Physician and patient factors associated with the prescribing of medications for sleep difficulties that are associated with high abuse potential or are expensive: An analysis of data from the National Ambulatory Medical Care Survey for 1996-2001 [J].
Rasu, RS ;
Shenolikar, RA ;
Nahata, MC ;
Balkrishnan, R .
CLINICAL THERAPEUTICS, 2005, 27 (12) :1970-1979
[10]   The pharmacokinetics of irbesartan in hypertensive children and adolescents [J].
Sakarcan, A ;
Tenney, F ;
Wilson, JT ;
Stewart, JJ ;
Adcock, KG ;
Wells, TG ;
Vachharajani, NN ;
Hadjilambris, OW ;
Slugg, P ;
Ford, NF ;
Marino, MR .
JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 41 (07) :742-749